Proactive Research analyst Emma Ulker discusses what she describes as the ground-breaking approach Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) is taking in the field of monoclonal antibodies. She says their lead programme Foralumab is notable in that not only is it the only fully human anti-CD3 specific mAb in clinical development, with broad potential for a range of inflammatory and autoimmune diseases, but also due to the novel proprietary formulations being developed by the company for nasal and oral administration.
Tiziana Life Sciences has potential to 'revolutionise treatment in monoclonal antibodies market'
Quick facts: Tiziana Life Sciences PLC
Price: 140.9 GBX
Market Cap: £269.74 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE